BXT GER Week ended 07 Aug 2026

Weekly Investor Report

BioNxt Solutions Inc. · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 0.20 EUR
7.8% latest week
Weekly setup

Mixed setup

The weekly trend is not active. Price is -33.9% below the Trend Line and sits at 5.8% of its 52-week range. The latest completed week returned 7.8%, after a 3.4% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal.

Setup score 19 out of 100
Latest Close 0.20 EUR 7 Aug 2026
1W Return 7.8% latest completed week
4W Return 3.4% short-term follow-through
12W Return -29.3% quarterly tape
Trend Breadth 28.8% 15 of 52 weeks active
Volume Ratio 0.4x vs 13-week average
What is working
  • Latest weekly return ranks in the strongest part of its sector group.
What could go wrong
  • The trend backdrop is inactive, so price action has not confirmed a constructive regime.
  • Price is below the Trend Line, which keeps downside pressure in focus.
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 7.8% Latest completed week; four-week move 3.4%. Indicator stack 16/38 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 40.10% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 50/100 0 relevant articles in the latest sentiment read.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is not active. Price is -33.9% below the Trend Line and sits at 5.8% of its 52-week range. The latest completed week returned 7.8%, after a 3.4% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul 7 Aug
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.0112-week average 0.07

12-week confirmation

Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is 3.4% over four weeks, -29.3% over 12 weeks, and -62.1% over one year. The current trend has remained active for 0 consecutive weeks.

Performance by holding period

1W7.8%
4W3.4%
12W-29.3%
26W-50.1%
52W-62.1%
Active trend streak0 weeks
Active weeks in one year15
Trend breadth28.8%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.86Latest activity-pressure read.
Pressure change46.2%Four-week change in activity pressure.
Leadership-52.77Latest relative-leadership reading.
RS change2.4%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 09 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 52% Model confidence 48%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength64/100Blend of value, momentum, and quality. Underlying universe rank 37; rank 1 is best.
Value54/100Relative valuation strength. Underlying universe rank 47; rank 1 is best.
Quality54/100Profitability and accounting quality. Underlying universe rank 47; rank 1 is best.
Momentum55/100Medium-term price momentum. Underlying universe rank 46; rank 1 is best.
Growth55/100Revenue and earnings growth. Underlying universe rank 46; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
-
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-13.4%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
-
Gross profit retained from each unit of revenue.
Operating margin
-
Operating profit retained from revenue.
Free-cash-flow margin
-
Free cash flow generated from revenue.
Return on invested capital
-
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
2/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-0.4%
Net share repurchases relative to market value.
Shareholder yield
-0.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-0.8x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity-

No recent insider transactions are stored for this company.

News sentiment50/100

Weighted news tone is neutral across 0 relevant articles.

0 positive · 0 neutral · 0 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings-No event is currently stored.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-70.5%Distance below the 52-week high.
13-week volatility9.2%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher10 of 2616 weeks finished lower.
Best week+10.4%Week of 26 Jun.
Worst week-17.9%Week of 10 Jul.
Latest week+7.8%Week of 7 Aug.

Shape of recent returns

Strong gains8
Modest gains2
Flat weeks0
Modest losses4
Sharp losses12
Recent vol9.2%13-week weekly-return volatility.
Base vol8.5%52-week weekly-return volatility.
Up/down split20/32Count of positive and negative weeks in the 52-week window.
Average skew6.8% / -6.7%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape18/100

Trend, activity pressure, participation, and risk combine to a 18/100 tape read.

 Indicator analysis9/100

Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.

Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 40.10%

Next-week expectancy is negative with a 40.10% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors56/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 92; Small Cap Core rank 57 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment50/100

Weighted news tone is neutral across 0 relevant articles.

 Insiders50/100

No recent insider transaction evidence is stored.

 Earnings50/100

No stored earnings event is currently attached to this ticker.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
7 Aug 20260.20 EUR7.8%0.30 EUR0.32 EUR-0.86-52.7736.4KOff
31 Jul 20260.18 EUR-17.8%0.31 EUR0.32 EUR-1.01-55.7898.5KOff
24 Jul 20260.23 EUR9.2%0.32 EUR0.32 EUR-1.16-45.8160.0KOff
17 Jul 20260.21 EUR6.7%0.32 EUR0.32 EUR-1.37-50.16182.5KOff
10 Jul 20260.19 EUR-17.9%0.33 EUR0.32 EUR-1.59-54.07176.2KOff
3 Jul 20260.23 EUR-4.1%0.34 EUR0.32 EUR-1.75-46.054.9KOff
26 Jun 20260.24 EUR10.4%0.34 EUR0.32 EUR-1.76-41.6733.8KOff
19 Jun 20260.22 EUR-3.1%0.35 EUR0.32 EUR-1.75-48.0935.6KOff
12 Jun 20260.23 EUR-8.4%0.36 EUR0.32 EUR-1.61-46.10633Off
5 Jun 20260.25 EUR-3.8%0.37 EUR0.33 EUR-1.51-41.86103.5KOff
29 May 20260.26 EUR0.8%0.37 EUR0.33 EUR-1.56-40.67109.3KOff
22 May 20260.26 EUR-8.5%0.38 EUR0.33 EUR-1.42-40.88156.0KOff
15 May 20260.28 EUR4.4%0.39 EUR0.33 EUR-1.23-33.20114.1KOff
8 May 20260.27 EUR-8.5%0.40 EUR0.33 EUR-0.94-37.1964.4KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.

Evidence context